These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Development of Robertson AKH; Ramogida CF; Schaffer P; Radchenko V Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444 [TBL] [Abstract][Full Text] [Related]
23. Advancements in cancer therapy with alpha-emitters: a review. Imam SK Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878 [TBL] [Abstract][Full Text] [Related]
25. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators. Kozempel J; Mokhodoeva O; Vlk M Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568 [TBL] [Abstract][Full Text] [Related]
26. From the magic bullet to an effective therapy: the peptide experience. Mansi L Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1393-8. PubMed ID: 15351914 [No Abstract] [Full Text] [Related]
27. An Overview of Targeted Alpha Therapy with Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998 [TBL] [Abstract][Full Text] [Related]
28. Astatine-211 imaging by a Compton camera for targeted radiotherapy. Nagao Y; Yamaguchi M; Watanabe S; Ishioka NS; Kawachi N; Watabe H Appl Radiat Isot; 2018 Sep; 139():238-243. PubMed ID: 29864741 [TBL] [Abstract][Full Text] [Related]
29. Radiation-based approaches for therapy and palliation of advanced prostate cancer. Lewis B; Sartor O Curr Opin Urol; 2012 May; 22(3):183-9. PubMed ID: 22453334 [TBL] [Abstract][Full Text] [Related]
30. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection. Cheetham PJ; Petrylak DP Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525 [TBL] [Abstract][Full Text] [Related]
31. Protein targeting constructs in alpha therapy. Olafsen T; Elgqvist J; Wu AM Curr Radiopharm; 2011 Jul; 4(3):197-213. PubMed ID: 22201709 [TBL] [Abstract][Full Text] [Related]
32. Cancer radioimmunotherapy with alpha-emitting nuclides. Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373 [TBL] [Abstract][Full Text] [Related]
34. Letter from the Editors. Sathekge MM; Bouchelouche K Semin Nucl Med; 2020 Mar; 50(2):115-117. PubMed ID: 32172794 [No Abstract] [Full Text] [Related]
35. Alpha particle therapy poised to become new line of cancer treatment. Kotz D J Nucl Med; 1998 Feb; 39(2):17N-19N, 36N. PubMed ID: 9476918 [No Abstract] [Full Text] [Related]
36. The promise of targeted {alpha}-particle therapy. Mulford DA; Scheinberg DA; Jurcic JG J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670 [TBL] [Abstract][Full Text] [Related]
37. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes. Morgenstern A; Bruchertseifer F; Apostolidis C Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390 [TBL] [Abstract][Full Text] [Related]
38. Radiolabelled somatostatins: towards the magic bullet? Buscombe JR; Caplin ME; Mielcarek W Nucl Med Commun; 1999 Apr; 20(4):299-301. PubMed ID: 10319345 [No Abstract] [Full Text] [Related]
39. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer? Allen BJ Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184 [No Abstract] [Full Text] [Related]
40. The Future of Radioligand Therapy: α, β, or Both? Haberkorn U; Giesel F; Morgenstern A; Kratochwil C J Nucl Med; 2017 Jul; 58(7):1017-1018. PubMed ID: 28408527 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]